Commercializing a novel spatial biology tools platform— Deterministic Barcoding in Tissue for spatial-omics sequencing (DBiT-seq)—that provides researchers and clinicians with unprecedented multi-omics maps of gene expression of tissue sections

By pinpointing specific changes in the varying cell groups of the central nervous system in neuro patients, DBiT-seq can help researchers better understand mechanisms of action and identify the safest and most effective approaches to drug discovery

—Ken Wang, CEO

Concarlo's innovative and patented IpY, a novel therapeutic peptide, will be the first to address CDK2 resistance, the first to target p27, and the first to inhibit both CDK4 and CDK2 at the same time. Concarlo targets a specific cellular pathway to kill tumor cells rather than just slowing their proliferation. The company relies on the role of p27Kip1 — a vital "ON-OFF" switch that regulates the activities of major cancer-related proteins CDK4, CDK6, and CDK2.

Concarlo Therapeutics is a woman-founded and run organization that is working toward revolutionizing the metastatic breast cancer field," says Dr. Stacy Blain, the company's Co-founder, & Chief Scientific Officer

Stacy Blain, Co-founder, & Chief Scientific Officer.

In 2016, Mary Gardner, the Founder and CEO,laid the foundation of DelNova. It is the only company in the industry that is developing a feasible solution, ReViVox™, to address botulinum toxin type A complications following aesthetic and medical neurotoxin therapies.Unlike others in the industry who have tried to resolve this issue by focusing on the toxin, DelNova addresses these complications ‘outside of the neuron.’ Its novel solution, ReViVox, acts as the perfect rescue product for all these complications without changing the toxin.DelNova is currently in the preclinical stage and is working toward collecting clinical data to validate the initial success of ReViVox. The company has already conducted a preliminary non-clinical proof of concept, collaborating with CRO partners to generate positive proof-of-concept data.

With Our Robust Solutions, We Offer Comfort And Assurance To Both Patients And Practitioners

—Mary Gardner, Founder and CEO

Gain Therapeutics is a preclinical biotechnology company focused on developing new medicines for protein misfolding diseases.

Gain Therapeutics Is The First Company To Successfully Combine Advancements In Computational Biology, Structural Biology, And Supercomputers To Develop Drugs

—Eric Richman, CEO

Gator Bio assists the R&D of therapeutic drugs with a best-in-class platform–Biolayer Interferometry (BLI)–that detects biomolecular interactions for rapid quantitation, kinetic measurements, epitope binning, and small molecule analysis. The BLI is a brilliant combination of engineering and sciences that results in revolutionary analytical technologies with superior performance and convenience at a fraction of the cost of traditional products.

The Gator Prime and the Gator Plus platforms comprehensively meet the needs of all small and medium biotech companies who are developing different therapeutics or biologics

Hong Tan, Founder and CEO

Developing gene therapies, antibodies, and regenerative platforms for treatment of cancer, malaria, and other diseases.

We are taking high-risk, high-reward approaches that are demonstrating activity against cancer and other urgent conditions

—Norman Lai, CTO, Vidal de la Cruz, CSO & Co-CEO, A. Murat Croci, Co-Founder & Co-CEO, Saule Dairabayeva, Markets Manager, Michael J. Karlin, Co-Founder & CBO

Kineta is a Seattle-based clinical-stage biotechnology company that sets itself on a mission to develop next-gen immunotherapies that transform patients’ lives. The company leverages its longstanding experience in immunology and in-depth expertise in innate immunity to develop first-in-class immunotherapies that address the challenges pertaining to current cancer therapies. By developing immuno-oncology drugs that use the body's innate immune system to fight cancer, they aim to improve the overall and long-term survival of cancer patients.

We believe that having a strong innate immune response will lead to a strong T-cell response; and together they can build a powerful shield against tumor cells

—Shawn Iadonato, PhD, CEO

Leukocare is a leading provider of bioinformatics based drug product formulation and development of technologies for the biological functionalization of medical devices, as well as the stabilization and protection of proteins. Leukocare stepped into the biopharmaceutical sector as a product development company almost 20 years ago;. It pioneered the development of a coating for filter membrane, employing an antibody to reduce the activity of neutrophil granulocytes.

We are highly specialized in stabilizing all kinds of biological molecules. And we have a very strong bioinformatics based approach which we apply to different project resulting in an optimized formulation using less drug substance in less times

Michael Scholl, CEO

MAIA Biotechnology is a targeted therapy immune-oncology company focused on developing and commercializing first-in-class drugs with novel mechanisms of action.

We envision testing THIO against as many tumor types and checkpoint combinations as possible to realize its full potential to benefit a large population of patients

—VladVitoc, Founder and CEO

MOBILion Systems’ structures for lossless ion manipulation (SLIM) technology provides unprecedented capability to separate clinically relevant molecules for MS analysis. It helps researchers drastically improve metabolic disease, drug, and biomarker discovery, paving the way for earlier disease detection, more accurate diagnostics, and reduced healthcare costs. More importantly, SLIM provides a very long, 13 meter path length to allow for maximum ion separation. As a result, researchers can use the arrival time as a fourth dimension of separation to accurately resolve isomers.

SLIM delivers critical quality attributes through high resolution, reproducibility, and speed to advance biotherapeutics

—Julie Sperry, Senior Vice President Biopharma Business